Max Robotics — Global Service Robot Directory + US Certification

About

Dr. Ying-Hsu Chang is a pioneering urologic surgeon and researcher whose work centers on advancing minimally invasive surgical techniques and deepening our understanding of prostate cancer biology. His most cited study, on robot-assisted laparoendoscopic single-site adrenalectomy (14 citations), demonstrates his commitment to refining surgical approaches that reduce patient trauma and improve cosmetic outcomes. Dr. Chang has made significant contributions to prostate cancer management, notably identifying clinical predictors of biochemical failure in patients with positive surgical margins after robotic-assisted radical prostatectomy—a critical insight for postoperative risk stratification. In a groundbreaking 2024 study (3 citations), he revealed that periprostatic adipose tissue may actually inhibit early-stage prostate tumor progression by secreting apoptotic factors, challenging conventional assumptions about obesity as a risk factor and suggesting a natural immune-mediated barrier. His most recent work (2025) simplifies risk assessment for hemorrhagic complications in robotic partial nephrectomy using tumor diameter and depth. With a career spanning from 2017 to present, Dr. Chang’s research bridges surgical innovation and tumor biology, offering practical tools for clinicians while opening new avenues for understanding cancer-microenvironment interactions.